Predictors of timely opioid agonist treatment initiation among veterans with and without HIV

Jessica Wyse, Jonathan Robbins, Kathleen A. McGinnis, E. Jennifer Edelman, Adam J. Gordon, Ajay Manhapra, David A. Fiellin, Brent A. Moore, Philip (Todd) Korthuis, Julie R. Gaither, Kirsha Gordon, Melissa Skanderson, Declan T. Barry, Stephen Crystal, Amy Justice, Kevin L. Kraemer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Opioid use disorder (OUD) is prevalent among people with HIV (PWH). Opioid agonist therapy (OAT) is the most effective treatment for OUD and is associated with improved health outcomes, but is often not initiated. To inform clinical practice, we identified factors predictive of OAT initiation among patients with and without HIV. Methods: We identified 19,698 new clinical encounters of OUD between 2000 and 2012 in the Veterans Aging Cohort Study (VACS), a national observational cohort of PWH and matched uninfected controls. Mixed effects models examined factors predictive of OAT initiation within 30-days of a new OUD clinical encounter. Results: 4.9% of both PWH and uninfected patients initiated OAT within 30 days of a new OUD clinical encounter. In adjusted models, participants with a psychiatric diagnosis (aOR = 0.54, 95% CI 0.47 – 0.62), PWH (aOR = 0.79, 95% CI 0.68–0.92), and rural residence (aOR = 0.56, 95% CI 0.39-0.78) had a lower likelihood of any OAT initiation, while African-American patients (aOR = 1.60, 95% CI 1.34–1.92), those with an alcohol related diagnosis (aOR = 1.76, 95% CI 1.48–2.08), diagnosis year 2005–2008 relative to 2000–2004 (aOR = 1.24, 95% CI 1.05–1.45), and patients with HCV (aOR = 1.50, 95% CI 1.27–1.77) had a greater likelihood of initiating any OAT within 30 days. Predictive factors were similar in the total sample and PWH only models. Conclusions: PWH were less likely to receive timely OAT initiation than demographically similar uninfected patients. Given the health benefits of such treatment, the low rate of OAT initiation warrants focused efforts in both PWH and uninfected populations.

Original languageEnglish (US)
Pages (from-to)70-75
Number of pages6
JournalDrug and Alcohol Dependence
Volume198
DOIs
StatePublished - May 1 2019

Fingerprint

Veterans
Opioid Analgesics
HIV
Therapeutics
Health
Insurance Benefits
Mental Disorders
African Americans
Cohort Studies
Aging of materials
Alcohols

Keywords

  • Buprenorphine
  • HIV
  • Methadone
  • Opioid agonist therapy
  • Opioid use disorder
  • Veterans affairs hospital

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. / Wyse, Jessica; Robbins, Jonathan; McGinnis, Kathleen A.; Edelman, E. Jennifer; Gordon, Adam J.; Manhapra, Ajay; Fiellin, David A.; Moore, Brent A.; Korthuis, Philip (Todd); Gaither, Julie R.; Gordon, Kirsha; Skanderson, Melissa; Barry, Declan T.; Crystal, Stephen; Justice, Amy; Kraemer, Kevin L.

In: Drug and Alcohol Dependence, Vol. 198, 01.05.2019, p. 70-75.

Research output: Contribution to journalArticle

Wyse, J, Robbins, J, McGinnis, KA, Edelman, EJ, Gordon, AJ, Manhapra, A, Fiellin, DA, Moore, BA, Korthuis, PT, Gaither, JR, Gordon, K, Skanderson, M, Barry, DT, Crystal, S, Justice, A & Kraemer, KL 2019, 'Predictors of timely opioid agonist treatment initiation among veterans with and without HIV', Drug and Alcohol Dependence, vol. 198, pp. 70-75. https://doi.org/10.1016/j.drugalcdep.2019.01.038
Wyse, Jessica ; Robbins, Jonathan ; McGinnis, Kathleen A. ; Edelman, E. Jennifer ; Gordon, Adam J. ; Manhapra, Ajay ; Fiellin, David A. ; Moore, Brent A. ; Korthuis, Philip (Todd) ; Gaither, Julie R. ; Gordon, Kirsha ; Skanderson, Melissa ; Barry, Declan T. ; Crystal, Stephen ; Justice, Amy ; Kraemer, Kevin L. / Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. In: Drug and Alcohol Dependence. 2019 ; Vol. 198. pp. 70-75.
@article{26e4bffe8bec4f6e9bbd6af5ff6411dc,
title = "Predictors of timely opioid agonist treatment initiation among veterans with and without HIV",
abstract = "Background: Opioid use disorder (OUD) is prevalent among people with HIV (PWH). Opioid agonist therapy (OAT) is the most effective treatment for OUD and is associated with improved health outcomes, but is often not initiated. To inform clinical practice, we identified factors predictive of OAT initiation among patients with and without HIV. Methods: We identified 19,698 new clinical encounters of OUD between 2000 and 2012 in the Veterans Aging Cohort Study (VACS), a national observational cohort of PWH and matched uninfected controls. Mixed effects models examined factors predictive of OAT initiation within 30-days of a new OUD clinical encounter. Results: 4.9{\%} of both PWH and uninfected patients initiated OAT within 30 days of a new OUD clinical encounter. In adjusted models, participants with a psychiatric diagnosis (aOR = 0.54, 95{\%} CI 0.47 – 0.62), PWH (aOR = 0.79, 95{\%} CI 0.68–0.92), and rural residence (aOR = 0.56, 95{\%} CI 0.39-0.78) had a lower likelihood of any OAT initiation, while African-American patients (aOR = 1.60, 95{\%} CI 1.34–1.92), those with an alcohol related diagnosis (aOR = 1.76, 95{\%} CI 1.48–2.08), diagnosis year 2005–2008 relative to 2000–2004 (aOR = 1.24, 95{\%} CI 1.05–1.45), and patients with HCV (aOR = 1.50, 95{\%} CI 1.27–1.77) had a greater likelihood of initiating any OAT within 30 days. Predictive factors were similar in the total sample and PWH only models. Conclusions: PWH were less likely to receive timely OAT initiation than demographically similar uninfected patients. Given the health benefits of such treatment, the low rate of OAT initiation warrants focused efforts in both PWH and uninfected populations.",
keywords = "Buprenorphine, HIV, Methadone, Opioid agonist therapy, Opioid use disorder, Veterans affairs hospital",
author = "Jessica Wyse and Jonathan Robbins and McGinnis, {Kathleen A.} and Edelman, {E. Jennifer} and Gordon, {Adam J.} and Ajay Manhapra and Fiellin, {David A.} and Moore, {Brent A.} and Korthuis, {Philip (Todd)} and Gaither, {Julie R.} and Kirsha Gordon and Melissa Skanderson and Barry, {Declan T.} and Stephen Crystal and Amy Justice and Kraemer, {Kevin L.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.drugalcdep.2019.01.038",
language = "English (US)",
volume = "198",
pages = "70--75",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Predictors of timely opioid agonist treatment initiation among veterans with and without HIV

AU - Wyse, Jessica

AU - Robbins, Jonathan

AU - McGinnis, Kathleen A.

AU - Edelman, E. Jennifer

AU - Gordon, Adam J.

AU - Manhapra, Ajay

AU - Fiellin, David A.

AU - Moore, Brent A.

AU - Korthuis, Philip (Todd)

AU - Gaither, Julie R.

AU - Gordon, Kirsha

AU - Skanderson, Melissa

AU - Barry, Declan T.

AU - Crystal, Stephen

AU - Justice, Amy

AU - Kraemer, Kevin L.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Background: Opioid use disorder (OUD) is prevalent among people with HIV (PWH). Opioid agonist therapy (OAT) is the most effective treatment for OUD and is associated with improved health outcomes, but is often not initiated. To inform clinical practice, we identified factors predictive of OAT initiation among patients with and without HIV. Methods: We identified 19,698 new clinical encounters of OUD between 2000 and 2012 in the Veterans Aging Cohort Study (VACS), a national observational cohort of PWH and matched uninfected controls. Mixed effects models examined factors predictive of OAT initiation within 30-days of a new OUD clinical encounter. Results: 4.9% of both PWH and uninfected patients initiated OAT within 30 days of a new OUD clinical encounter. In adjusted models, participants with a psychiatric diagnosis (aOR = 0.54, 95% CI 0.47 – 0.62), PWH (aOR = 0.79, 95% CI 0.68–0.92), and rural residence (aOR = 0.56, 95% CI 0.39-0.78) had a lower likelihood of any OAT initiation, while African-American patients (aOR = 1.60, 95% CI 1.34–1.92), those with an alcohol related diagnosis (aOR = 1.76, 95% CI 1.48–2.08), diagnosis year 2005–2008 relative to 2000–2004 (aOR = 1.24, 95% CI 1.05–1.45), and patients with HCV (aOR = 1.50, 95% CI 1.27–1.77) had a greater likelihood of initiating any OAT within 30 days. Predictive factors were similar in the total sample and PWH only models. Conclusions: PWH were less likely to receive timely OAT initiation than demographically similar uninfected patients. Given the health benefits of such treatment, the low rate of OAT initiation warrants focused efforts in both PWH and uninfected populations.

AB - Background: Opioid use disorder (OUD) is prevalent among people with HIV (PWH). Opioid agonist therapy (OAT) is the most effective treatment for OUD and is associated with improved health outcomes, but is often not initiated. To inform clinical practice, we identified factors predictive of OAT initiation among patients with and without HIV. Methods: We identified 19,698 new clinical encounters of OUD between 2000 and 2012 in the Veterans Aging Cohort Study (VACS), a national observational cohort of PWH and matched uninfected controls. Mixed effects models examined factors predictive of OAT initiation within 30-days of a new OUD clinical encounter. Results: 4.9% of both PWH and uninfected patients initiated OAT within 30 days of a new OUD clinical encounter. In adjusted models, participants with a psychiatric diagnosis (aOR = 0.54, 95% CI 0.47 – 0.62), PWH (aOR = 0.79, 95% CI 0.68–0.92), and rural residence (aOR = 0.56, 95% CI 0.39-0.78) had a lower likelihood of any OAT initiation, while African-American patients (aOR = 1.60, 95% CI 1.34–1.92), those with an alcohol related diagnosis (aOR = 1.76, 95% CI 1.48–2.08), diagnosis year 2005–2008 relative to 2000–2004 (aOR = 1.24, 95% CI 1.05–1.45), and patients with HCV (aOR = 1.50, 95% CI 1.27–1.77) had a greater likelihood of initiating any OAT within 30 days. Predictive factors were similar in the total sample and PWH only models. Conclusions: PWH were less likely to receive timely OAT initiation than demographically similar uninfected patients. Given the health benefits of such treatment, the low rate of OAT initiation warrants focused efforts in both PWH and uninfected populations.

KW - Buprenorphine

KW - HIV

KW - Methadone

KW - Opioid agonist therapy

KW - Opioid use disorder

KW - Veterans affairs hospital

UR - http://www.scopus.com/inward/record.url?scp=85062837746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062837746&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2019.01.038

DO - 10.1016/j.drugalcdep.2019.01.038

M3 - Article

VL - 198

SP - 70

EP - 75

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

ER -